| dbo:abstract
|
- John Mendelsohn (* 31. August 1936 in Cincinnati, Ohio; † 7. Januar 2019) war ein US-amerikanischer Onkologe am University of Texas MD Anderson Cancer Center in Houston, Texas. Er machte sich um die klinische Entwicklung von Cetuximab verdient, ein therapeutischer chimärer monoklonaler Antikörper vom Typ IgG1 gegen den Epidermalen Wachstumsfaktor-Rezeptor (EGFR), der in der Onkologie (Krebsmedizin) zur Krebsimmuntherapie eingesetzt wird. Mendelsohn erwarb 1958 an der Harvard University einen Bachelor in Biochemie und 1963 an der Harvard Medical School einen M.D. als Abschluss des Medizinstudiums. Akademische Stationen (Professuren) waren die University of California, San Diego (1970–1985), Cornell University und Sloan-Kettering Institute for Cancer Research (1985–1996) und University of Texas MD Anderson Cancer Center (ab 1996). (de)
- John Mendelsohn (August 31, 1936 – January 7, 2019) was a president of the University of Texas MD Anderson Cancer Center in Houston. He was an internationally recognized leader in cancer research. Mendelsohn served as MD Anderson president from 1996 to 2011. When Ronald DePinho became president, he stepped down September 1, 2011. Mendelsohn remained on the faculty as co-director of the new Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy. Also, he was a senior fellow in health and technology at the Baker Institute. Mendelsohn was only the third full-time president of MD Anderson. When he arrived, Mendelsohn's focus shifted from his expertise in laboratory research and clinical trials to leading an institution that employs about 18,000 people and serves 100,000 patients yearly, with a budget of more than $3.3 billion. (en)
- Джон Мендельсон (John Mendelsohn; 31 августа 1936 — 7 января 2019) — американский онколог.Сотрудник MD Anderson Cancer Center, член Национальной медицинской академии США (1997) и Нидерландской королевской академии наук (1999).Разработчик цетуксимаба. (ru)
- 約翰·曼德森（英語：John Mendelsohn，1936年8月31日－2019年1月7日)，研發出第一種標靶藥物Erbitux（爾必得舒）的醫學家。和東尼·杭特（Tony Hunter）、布萊恩·德魯克爾（Brian J. Druker）一同獲得2018年唐獎生技醫藥獎。2019年1月7日因腦癌去世。 (zh)
|
| dbo:almaMater
| |
| dbo:birthDate
| |
| dbo:birthPlace
| |
| dbo:deathDate
| |
| dbo:deathPlace
| |
| dbo:institution
| |
| dbo:thumbnail
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 11319 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:almaMater
|
- Harvard University (en)
- Memorial Sloan Kettering Cancer Center (en)
- (en)
- Cornell University Medical College (en)
|
| dbp:birthDate
| |
| dbp:birthPlace
|
- Cincinnati, Ohio, U.S. (en)
|
| dbp:deathDate
| |
| dbp:deathPlace
|
- Houston, Texas, U.S. (en)
|
| dbp:wikiPageUsesTemplate
| |
| dbp:workplaces
|
- University of California, San Diego (en)
- (en)
- MD Anderson Cancer Center (en)
- Baker Institute (en)
|
| dcterms:subject
| |
| gold:hypernym
| |
| schema:sameAs
| |
| rdf:type
| |
| rdfs:comment
|
- Джон Мендельсон (John Mendelsohn; 31 августа 1936 — 7 января 2019) — американский онколог.Сотрудник MD Anderson Cancer Center, член Национальной медицинской академии США (1997) и Нидерландской королевской академии наук (1999).Разработчик цетуксимаба. (ru)
- 約翰·曼德森（英語：John Mendelsohn，1936年8月31日－2019年1月7日)，研發出第一種標靶藥物Erbitux（爾必得舒）的醫學家。和東尼·杭特（Tony Hunter）、布萊恩·德魯克爾（Brian J. Druker）一同獲得2018年唐獎生技醫藥獎。2019年1月7日因腦癌去世。 (zh)
- John Mendelsohn (* 31. August 1936 in Cincinnati, Ohio; † 7. Januar 2019) war ein US-amerikanischer Onkologe am University of Texas MD Anderson Cancer Center in Houston, Texas. Er machte sich um die klinische Entwicklung von Cetuximab verdient, ein therapeutischer chimärer monoklonaler Antikörper vom Typ IgG1 gegen den Epidermalen Wachstumsfaktor-Rezeptor (EGFR), der in der Onkologie (Krebsmedizin) zur Krebsimmuntherapie eingesetzt wird. (de)
- John Mendelsohn (August 31, 1936 – January 7, 2019) was a president of the University of Texas MD Anderson Cancer Center in Houston. He was an internationally recognized leader in cancer research. Mendelsohn served as MD Anderson president from 1996 to 2011. When Ronald DePinho became president, he stepped down September 1, 2011. Mendelsohn remained on the faculty as co-director of the new Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy. Also, he was a senior fellow in health and technology at the Baker Institute. (en)
|
| rdfs:label
|
- John Mendelsohn (Mediziner) (de)
- John Mendelsohn (doctor) (en)
- Мендельсон, Джон (ru)
- 約翰·曼德森 (醫學家) (zh)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageDisambiguates
of | |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
